**Evaluating clinicopathological profiling and treatment outcomes in Gastric cancer patients: a single institution experience**

Karim Mashhour, MD, Menna Rady, MD, Mina Nashaat, Msc1,Emad Habib, MD

Kasralainy Center of Clinical Oncology and Nuclear Medicine, Cairo University, Cairo, Egypt

E-mail: [karim.mashhour.81@gmail.com](mailto:karim.mashhour.81@gmail.com)

**Abstract: Background:** Stomach cancer remains a major health problem in Egypt despite developments in diagnostic and therapeutic modalities with poor prognosis mainly due to its late-stage presentation, which is why it carries a burden on health and society. **Aim of the study:** to evaluate the incidence rate of gastric cancer among the patients treated at Kasr Al-Ainy Center of Clinical Oncology and Nuclear medicine (NEMROCK) as well as to correlate with patient’s demographic and clinico-pathological characteristics and treatment outcome. **Patients and methods:** this is a retrospective study to evaluate the gastric cancer patients and their characteristics who received treatment at NEMROCK during the period from 2016 till 2020 and their data were extracted from the electronic database archive. **Results:** our series included 89 patients, Males and females have almost equal proportions among the included patients 50.6% versus 49.4% respectively where their median age was 54 years at the time of diagnosis, 56.2% of the included patients presented at an advanced stage with metastasis at their first presentation. Our study confirmed the impact of surgical resection on improving the survival where the median OS of patients who underwent surgical resection was 17.4 months Vs 8.4 months for those who didn’t have surgical resection, we also observed that neoadjuvant therapy used in the locally advanced disease cases improved the median OS to 16.7 months (p value 0.0009). **Conclusion:** Surgical resection, use of neoadjuvant chemotherapy and poor histo-pathologic features correlate with the treatment outcomes in gastric cancers treated at our institution.

[Karim Mashhour, Menna Rady, Mina Nashaat, Emad Habib. **Evaluating clinicopathological profiling and treatment outcomes in Gastric cancer patients: a single institution experience.** Cancer Biology 2022;12(4):257-266]. ISSN: 2150-1041 (print); ISSN: 2150-105X (online). <http://www.cancerbio.net>  [03.doi](http://www.sciencepub.net/nature.%20%20x.doi):[10.7537/marscbj120422.03.](http://www.dx.doi.org/10.7537/marscbj120422.03)

**Keywords:** Gastric cancer, Clinico-pathological features, Treatment, Risk factors

**1. Introduction:**

Gastric cancer is the 5thmost frequently diagnosed cancer and the 3rdleading cause of cancer death (after lung cancer, breast cancer, prostate cancer, and colorectal cancer in incidence, after lung cancer and colorectal cancer in mortality) according to GLOBOCAN 2018 estimates**(1)**.

Stomach cancer rates are reported to be decreasing in developed countries due to improved nutrition, better food preservation, better prevention, earlier diagnosis, and better treatment modalities. However, the scenario in Egypt is different, as most patients present at an end-stage with an impact on their overall survival and quality of life.

Globally it is the 12thmost common cancer in both sexes, accounting for 1.6% of all cancers with approximately 1,271 new patients in 2015. GC is the 12th leading cause of cancer death, accounting for 2.2% of all cancer deaths in Egypt. As reported in several Egyptian population-based cancer registries, the mean age of patients with GC is 56 years, while the incidence increases with age, 55% of cases occurring from 50 years of age. to 70 years **(2)**.

The majority of gastric cancers are associated with a variety of pathogenic infections, including but not limited to Helicobacter pylori (*H. pylori*) and Epstein-Barr virus (EBV). Strategies are being pursued to prevent the development of gastric cancer, such as the eradication of *H. pylori*, which helped to prevent in a significant proportion of gastric cancer cases **(3-4)**.

It is recently believed that Gastric cancer is a very heterogenous disease, there are three subtypes according to Lauren classification (well differentiated, poorly differentiated and mixed disease) and four subtypes according to the WHO classification system (papillary, tubular, signet ring and mucinous)**(5-6)**, in addition to molecular markers such as HER2 status **(7-8)**.

Surgery is the most effective treatment for the non-metastatic gastric cancer and the cure rate for T1 can reach 90% after surgery. However, many patients with locally advanced stomach cancer, even those with R0 resection will experience tumor recurrence within one year of surgery **(9-10)**.

Numerous studies have demonstrated the importance of neoadjuvant treatment and its impact on local control with reduction of lymph node metastasis rate, the aim of the neoadjuvant treatment is to achieve down-staging of the tumor, improvement of the tumor resection rate (R0), prolong the postoperative overall survival and progression-free survival for locally advanced resectable cases when combined with surgery **(11-13).**

Stomach cancer is still a burden on health and society as it carries poor prognosis with an overall survival of around 25% worldwide **(14)** as most of the cases are diagnosed at an advanced stage leading to poor overall outcome with metastases and chemotherapy resistance. These data suggest the need for more effective molecular therapeutic strategies, especially with the success and challenges of newly available therapeutic agents emerging.

This study assesses the incidence of gastric cancer and examines the demographic and clinical pathological characteristics of patients and the impact of various therapies used at our center on overall survival and progression-free survival. The impact of neoadjuvant therapy was studied as well.

**2. Material and methods:**

This is a Retrospective study of Gastric cancer patients treated at Kasr Al-Ainy center of Clinical Oncology and Nuclear medicine during the period from January 2016 to December 2020. The study design and documents were approved by the institutional review board of the Kasr al Ainy center of Clinical Oncology and nuclear medicine (NEMROCK). (Ethical committee number MS-492-2021).

We accessed the database to extract the file number of the patients. Our series included 89 patients. Data were retrieved from patients' records, including age at diagnosis, year of diagnosis, gender, demographic features, clinical and histo-pathological data, neoadjuvant therapy and other treatment modalities as well as the date of the last follow up. The disease stage was determined according to the 8th edition of the UICC/AJCC TNM classification. Patients with insufficient data were excluded.

Overall survival (OS) was defined as the time in months from the date of diagnosis till the date of death, last date known to be alive, or date of the study cut off. Progression-free survival (PFS) was defined as the time in months from the start of treatment till the date of progression of disease or death.

**Inclusion criteria:**

* Adult patients aged> 18 years old
* Pathologically proven gastric and gastro-esophageal adenocarcinoma.
* All patients received active therapy for their disease (whether surgery, Radiation or Chemotherapy).
* Different stages of the disease (early, locally advanced, or metastatic).
* Patients with controlled co-morbidities such as diabetes Mellitus were included in this study.

**Exclusion criteria:**

* Patients with incomplete or missing data.
* Patients with another histopathology (e.g., GIST or lymphoma).

The primary outcome of this analysis was to identify the prevalence of gastric cancer at our institution during the period of the study (2016-2020), define the clinico-pathological features of various stages of gastric cancer and to correlate between different treatment protocols used to treat patients with gastric cancer according to the stage (surgery, radiotherapy, and chemotherapy) and its impact on progression-free survival (PFS) and overall survival (OAS).

**Statistical analysis*:***

Statistical analysis was conducted using SPSS (statistical package for the social science) 22nd edition. Quantitative variables were presented in mean ± standard deviation and range, qualitative variables were presented in frequency and percentage, and were compared using Chi2 test. Log-rank test was used to assess risk factors associated with poor survival outcomes. Multivariate cox hazard proportional test was conducted to assess the hazard ratio for the development of poor survival outcomes. Kaplan Meier curves were constructed to visualize the survival rates among study groups. A probability value (P-value) less than 0.05 will be considered significant.

**3. Results:**

In this study, we reviewed the medical files of 102 patients diagnosed with primary gastric adenocarcinoma who sought medical advice at Kasr AL-Ainy center of clinical oncology and nuclear medicine during the period from the beginning of 2016 till the end of 2020. Only 89 patients with complete clinical records and follow-up data were included in this study. The relative frequency of gastric cancers of all patients who were diagnosed with GIT malignancies for the sample period was 1%.

**The demographic data**

Of the 89 patients, Males and females have almost equal proportions among the included patients 50.6% versus 49.4% respectively. The mean age was 53.5± 13.9 years old, and the range was 23-82 years. The Median age was 54 years at diagnosis and most of the patients’ ages lied between the age group of 40 to 60 years old.

Most of our patients were nonsmokers, where smokers represented only 23.6% of the included patients, 27% of the patients had co-morbidities and hypertension was the commonest co-morbidity. All demographic data are shown in the table (1).

**Table 1:Demographics of the included patients**

|  |  |  |  |
| --- | --- | --- | --- |
|  | | **Mean± SD/ Count** | **Range / %** |
| **Age** | Mean ± SD, range | 53.5± 13.9 | 23-82 |
| Below 40 years | 16 | 18% |
| 40-60 years | 44 | 49.5% |
| Above 60 years | 29 | 32.5% |
| **Gender** | Female | 45 | 50.6% |
| Male | 44 | 49.4% |
| **Comorbidities** | None | 65 | 73.0% |
| Hypertension | 12 | 13.5% |
| HTN and diabetes | 5 | 5.6% |
| Diabetes mellitus | 7 | 7.9% |
| **Smoking** | No | 68 | 76.4% |
| Yes | 21 | 23.6% |

The majority of the reported cases were adenocarcinoma, 57.3% of them had signet ring appearance subtype. The majority of patients had grade 3 tumors (53.9%), most of the tumors were located at the lower third of the stomach (43.8%) and 7 patients had linitis plastica where the whole stomach was affected.

The majority of the included patients presented by advanced disease (T3 and T4) (59.6%), while patients with early disease (T1 and T2) were 30.3%, and 9 (10.1%) patients could not be assessed for tumor size. The majority were node positive 54 (60.6%) and 35 cases were node negative (39.2%). **(Figure 1&2)**

The metastatic work up showed that more than half of the patients presented with metastasis (56.2%), and the most common site of metastasis was the Peritoneum followed by the liver and abdominal lymph nodes and multiple sites of metastasis were observed in 15.7% of the patients. The pathological data and TNM staging are outlined in Table 2.

**Treatment modalities**

**Surgery;**

The aim of treatment was curative in 39 patients (43.8%) and palliative in 50 patients (56.2%). Surgery with curative intent was performed in 41 patients (46.1%). Subtotal gastrectomy was the commonest procedure (53.6%) and R0 resection could be achieved in all cases (100%). No Laparoscopic surgery was done for any patient, where all patients underwent open surgery.

Regarding nodal dissection, D1 dissection was the commonest procedure where it was conducted in 34 (82.9%) patients and D2 dissection in 7 (17.1%) cases.

**Table 2: Pathological and TNM staging of the included patients**

|  |  |  |  |
| --- | --- | --- | --- |
|  | | **Count** | **%** |
| **Pathology Type** | Adenocarcinoma | 84 | 94.4% |
| Anaplastic carcinoma | 5 | 5.6% |
| **Signet ring appearance** | No | 38 | 42.7% |
| Yes | 51 | 57.3% |
| **Grade** | I | 1 | 1.1% |
| II | 25 | 28.1% |
| III | 48 | 53.9% |
| IV | 15 | 16.9% |
| **Tumor site** | Upper third | 23 | 25.8% |
| Middle third | 20 | 22.5% |
| Lower third | 39 | 43.8% |
| Whole Stomach (linitis Plastica) | 7 | 7.9% |

|  |  |  |  |
| --- | --- | --- | --- |
| **TNM staging** | | **Count** | **%** |
| **T staging** | Tx | 9 | 10.1% |
| Early disease | 27 | 30.3% |
| Late disease | 53 | 59.6% |
| **Nodal status** | N0 | 35 | 39.3% |
| N1 | 16 | 18.0% |
| N2 | 28 | 31.5% |
| N3 | 10 | 11.2% |
| **Metastasis** | M0 | 39 | 43.8% |
| M1 | 50 | 56.2% |




Figure 1: Pie chart showing the T stage among the included patients


****

Figure 2: Bar chart illustrating nodal stage at presentation

**Radiation therapy:**

Radiation was prescribed in 30 (33.7%) patients, where the aim of radiation was in an adjuvant setting for 25 patients with a dose assigned as 45 Gy/ 25fractions / 5weeks protocol concurrent with fluropyrdimine based chemotherapy.

Radiation was prescribed on a palliative basis locally to the stomach in 5 patients to stop bleeding, three patients with a dose prescribed of 30 Gy/ 10 fractions/ 2 weeks. Whereas two patients with a dose prescribed of 20 Gy/ 5 fractions / 1 week.

**Table 3: Modalities of treatment used in the treatment of the cohort of patients**

|  |  |  |  |
| --- | --- | --- | --- |
| **Surgery** | | **Count** | **%** |
| **Surgery** | No | 48 | 53.9% |
| Yes | 41 | 46.1% |
| **Type of surgery** | Sub-total | 22 | 53.6% |
| Total | 19 | 46.4% |
| **Lymphadenectomy** | D1 | 34 | 82.9% |
| D2 | 7 | 17.1% |

|  |  |  |  |
| --- | --- | --- | --- |
| **Radiotherapy** | | **Count** | **%** |
| **Radiation** | No | 59 | 66.3% |
| Yes | 30 | 33.7% |
| **Aim of radiation** | Adjuvant | 25 | 83.3% |
| Palliative | 5 | 16.7% |
| **Dose of Radiation** | 2000/5# | 2 | 6.7% |
| 3000/10# | 3 | 10.0% |
| 45/25# | 25 | 83.3% |
| **Type of Concurrent chemotherapy** | 5FU | 13 | 52.0% |
| Xeloda | 12 | 48.0% |

|  |  |  |  |
| --- | --- | --- | --- |
| **Chemotherapy** | | **Count** | **%** |
| **Chemotherapy** | No | 9 | 19.1% |
| Yes | 80 | 80.9% |
| **Aim of chemotherapy** | Neoadjuvant | 16 | 20.0% |
| Adjuvant | 15 | 18.7% |
| Palliative | 49 | 61.3% |
| **Palliative chemotherapy - Number of cycles** | 1 | 8 | 16.3% |
| 2 | 3 | 6.1% |
| 3 | 13 | 26.5% |
| 4 | 6 | 12.2% |
| 5 | 1 | 2.1% |
| 6 | 14 | 28.6% |
| 8 | 3 | 6.1% |
| 9 | 1 | 2.1% |


**Chemotherapy:**

Neoadjuvant chemotherapy was used in seventeen patients (19.1%), the neoadjuvant chemotherapy protocol was mainly a fluoropyrimidine based regimen (FOLFOX in most of cases) followed by ECF protocol (anthracycline-based regimen).

Fifteen patients received Adjuvant Chemotherapy; Anthracycline-based regimens were the first to be used but they were accompanied by great toxicity. Then Fluoropyrimidine based regimens were the commonly used.

Palliative chemotherapy was prescribed in 49 patients (55.1%), where fluoropyrimidine based chemotherapy was used in the majority of patients (59.2%) as first line, where FOLFOX was the commonest protocol used and the most tolerable one, only 3 patients with a poor performance status were treated by single agents**(Figure 3)**.

Eighteen patients received second line chemotherapy after progression on the first line and the Carboplatin/taxol regimen was the most commonly used. Table 2 illustrates the modalities used in treating the patients recruited in our study.

****

**Figure 3: Chemotherapy regimens used on palliative basis as first line among the included patients**

**Chart, histogram

Description automatically generated**

**Figure 4: Kaplan Meier curves showing OS according to presence of signet ring appearance in pathology**

**Overall Survival analysis**

Among the included cohort of patients, we observed a median of OS 10.7 months, with a 95% CI (8.3-13.2 months). There was a statistically significant difference in OS according to presence of signet ring appearance in the histopathology examination with a p-value of 0.005 **(Figure 4)**.

Comparison of OS based on histological grade of the cancer cells showed that there was statistically significant difference in OS between groups with a p-value of 0.004. Comparison of OS based with respect to the nodal status showed that there was statistically significant difference in OS between the study groups according to nodal status with a p-value of 0.0001. Comparing OS based on disease stage showed that, there was a statistically significant difference in OS between disease stages as an advanced disease stage was associated with shorter OS with p-values = 0.007. There was a statistically significant difference of OS based on metastatic disease as M1 disease was associated with significantly shorter OS with p-values = 0.008. Patients who underwent surgical resection had a significantly longer OS with p-values = 0.0001. Patients who received neoadjuvant chemotherapy showed significantly longer OS with p-values = 0.0009. Patients with stationary or regressive disease after first line chemotherapy was associated with longer OS compared to progressive disease with p-values = 0.032.

**Progression free survival analysis**

In the current cohort of patients, the median PFS was 24.5 months (95% CI 12.5-36.5 months). Progression free survival showed a statistically significant difference between nodal positive and node negative disease with a p-value of 0.04 **(Figure 5).** PFS was significantly shorter among patients with progressive disease after first line of chemotherapy with a p-value of 0.012.

**Table 4: Factors influencing OAS among the study group**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Signet ring appearance** |  | | | | **P value** |
| **Median OS** | **Std. Error** | **95% Confidence Interval** | |
| **Lower Bound** | **Upper Bound** |
| **No** | 17.405 | 1.113 | 15.223 | 19.587 | 0.005 |
| **Yes** | 13.067 | 0.684 | 11.726 | 14.409 |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Grade** |  | | | | **P value** |
| **Median OS** | **Std. Error** | **95% Confidence Interval** | |
| **Lower Bound** | **Upper Bound** |
| **Low grade (II)** | 16.985 | 1.564 | 13.920 | 20.050 | 0.004 |
| **High grade (III-IV)** | 11.637 | 0.648 | 10.366 | 12.908 |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Nodal status** |  | | | | **P value** |
| **Median OS** | **Std. Error** | **95% Confidence Interval** | |
| **Lower Bound** | **Upper Bound** |
| **Node negative** | 17.531 | 1.646 | 14.304 | 20.758 | 0.0001 |
| **Node positive** | 10.061 | 0.741 | 8.608 | 11.514 |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Stage** |  | | | | **P value** |
| **Median OS** | **Std. Error** | **95% Confidence Interval** | |
| **Lower Bound** | **Upper Bound** |
| **I-II** | 17.500 | 0.930 | 15.678 | 19.322 | 0.007 |
| **III-IV** | 8.933 | 1.137 | 6.705 | 11.161 |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Metastasis** |  | | | | **P value** |
| **Median OS** | **Std. Error** | **95% Confidence Interval** | |
| **Lower Bound** | **Upper Bound** |
| **M0** | 16.100 | 4.008 | 8.244 | 23.956 | 0.008 |
| **M1** | 9.833 | 1.237 | 7.409 | 12.258 |
| **Overall** | 10.767 | 1.255 | 8.306 | 13.227 |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Surgery** | **Median OS** | **Std. Error** | **95% Confidence Interval** | | **P value** |
| **Lower Bound** | **Upper Bound** |
| **No** | 8.467 | 0.944 | 6.617 | 10.316 | 0.0001 |
| **Yes** | 17.400 | 1.938 | 13.602 | 21.198 |
| **Overall** | 10.767 | 1.255 | 8.306 | 13.227 |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Neoadjuvant chemotherapy** |  | | | | **P value** |
| **Median OS** | **Std. Error** | **95% Confidence Interval** | |
| **Lower Bound** | **Upper Bound** |
| **No** | 9.867 | 1.195 | 7.524 | 12.209 | 0.009 |
| **Yes** | 16.567 | 3.859 | 9.003 | 24.131 |
| **Overall** | 10.767 | 1.255 | 8.306 | 13.227 |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Assessment post chemotherapy** |  | | | | **P value** |
| **Median OS** | **Std. Error** | **95% Confidence Interval** | |
| **Lower Bound** | **Upper Bound** |
| **Stationary** | 17.733 | 4.234 | 9.434 | 26.032 | 0.032 |
| **Regression** | 17.467 | 7.163 | 3.426 | 31.507 |
| **Progression** | 9.867 | 1.447 | 7.031 | 12.702 |
| **Overall** | 10.767 | 1.255 | 8.306 | 13.227 |

**Cox hazard proportional test**

**Overall survival:**

Cox hazard proportional test showed that surgical resection was associated with a lower hazard of death with a p-value of 0.005, and HR 6.2 (95% CI 1.7-22.1).

**Progression free survival:**

Cox hazard proportional test showed that hypertension and progression after first line was an independent risk factor for shorter PFS with p-values = 0.022 and 0.046, and HR 11.2 (95% CI 1.4 – 89.2) and 20.8 (95% CI 1.05-409.8) respectively.

**Chart, box and whisker chart

Description automatically generated**

**Figure 5: Kaplan Meier curves showing PFS according to nodal status**

**Table 5:Cox hazard proportional test for overall survival among the included patients**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Factors** | **Correlation coefficient** | **P value** | **HR** | **95.0% CI** | |
| **Lower** | **Upper** |
| **Gender** | 0.597 | 0.052 | 1.816 | 0.995 | 3.315 |
| **Comorbidities (DM)** | -0.296 | 0.831 | 0.744 | 0.049 | 11.290 |
| **Comorbidities (HTN and DM)** | -0.024 | 0.988 | 0.976 | 0.047 | 20.321 |
| **Comorbidities (HTN)** | -0.046 | 0.978 | 0.955 | 0.037 | 24.400 |
| **Signet ring appearance** | 0.262 | 0.484 | 1.299 | 0.625 | 2.701 |
| **Grade (I)** | 1.017 | 0.306 | 2.765 | 0.394 | 19.410 |
| **Grade (II)** | 0.128 | 0.780 | 1.136 | 0.463 | 2.787 |
| **Grade (III)** | -0.554 | 0.141 | 0.575 | 0.275 | 1.202 |
| **T1** | -1.382 | 0.029 | 0.251 | 0.073 | 0.866 |
| **T2** | -1.463 | 0.029 | 0.232 | 0.062 | 0.859 |
| **T3** | -0.422 | 0.410 | 0.655 | 0.240 | 1.789 |
| **T4** | -0.643 | 0.171 | 0.526 | 0.210 | 1.320 |
| **N0** | 0.092 | 0.901 | 1.097 | 0.255 | 4.718 |
| **N1** | 0.171 | 0.819 | 1.187 | 0.273 | 5.165 |
| **N2** | 0.806 | 0.185 | 2.240 | 0.679 | 7.384 |
| **M1** | 0.505 | 0.496 | 1.657 | 0.388 | 7.083 |
| **Stage (I)** | 0.287 | 0.849 | 1.332 | 0.069 | 25.673 |
| **Stage (II)** | 1.505 | 0.109 | 4.502 | 0.714 | 28.403 |
| **Stage (III)** | -0.276 | 0.719 | 0.759 | 0.168 | 3.424 |
| **Surgery** | 1.823 | 0.005 | 6.188 | 1.733 | 22.095 |
| **Neoadjuvant chemotherapy** | 1.242 | 0.090 | 3.462 | 0.823 | 14.560 |
| **Relapse** | -0.409 | 0.542 | 0.664 | 0.179 | 2.472 |

**Table 6:Cox hazard proportional test for progression free survival among the included patients**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Factors** | **Correlation coefficient** | **P value** | **HR** | **95% CI** | |
| **Lower** | **Upper** |
| **Gender** | 2.490 | 0.007 | 12.060 | 1.944 | 74.811 |
| **DM** | -0.125 | 0.911 | 0.883 | 0.099 | 7.851 |
| **DM and HTN** | 0.130 | 0.908 | 1.138 | 0.128 | 10.133 |
| **HTN** | 2.424 | 0.022 | 11.290 | 1.428 | 89.256 |
| **Pathology** | -13.670 | 0.989 | 0.000 | 0.000 | 0.000 |
| **Signet ring appearance** | -1.629 | 0.085 | 0.196 | 0.031 | 1.251 |
| **Grade II** | -0.084 | 0.925 | 0.920 | 0.159 | 5.309 |
| **Grade III** | -1.007 | 0.243 | 0.365 | 0.068 | 1.978 |
| **Surgery** | -10.684 | 0.990 | 0.000 | 0.000 | 0.000 |
| **Neoadjuvant chemotherapy** | -0.241 | 0.724 | 0.786 | 0.207 | 2.990 |
| **Stationary** | -0.040 | 0.959 | 0.961 | 0.211 | 4.371 |
| **Progression** | 3.036 | 0.046 | 20.825 | 1.058 | 409.814 |
| **Regression** | 0.583 | 0.532 | 1.792 | 0.288 | 11.168 |

**4. Discussion**

In Egypt, Gastric cancer is the 12thmost common cancer in both sexes, accounting for 1.6% of al cancers with approximately 1,271 new patients in 2015. GC is the 12thleading cause of cancer death, accounting for 2.2% of all cancer deaths in Egypt. As reported in several Egyptian population-based cancer registries **(2)**.

The importance of our study is that it shows the relative frequency of gastric cancer patients treated at Kasr Al-Ainy center of Clinical Oncology and Nuclear medicine, the different clinico-pathological features of Gastric cancer patients, and the impact of the different treatment modalities used on their PFS and OS as Gastric cancer is a burden on health and society.

In our study, 102 cases with Gastric cancer were retrieved from our medical records in the period from the start of 2016 till the end of 2020.And only 89 patients with complete data were included in the study. The median age of patients at our study was 54 years with extremes of 23 and 79 years of age but most of the included patients’ age lied between the age group of 40-60 years which is consistent with recent studies that predict the incidence of gastric cancer tends to be in younger age groups (younger than 50 years old)**(15)**

Hypertension among the included patients was an independent prognostic risk factor for shorter PFS. Moreover, most of the patients in this study had signet ring appearance subtype (57.3%), in our series the presence of signet ring appearance was associated with median OS 11.8 months VS 8.4 months for those with No signet ring appearance. However, there was no statistically significant difference between the two groups. The impact of the signet ring pathology on the prognosis in advanced cases is controversial but it is commonly known to be poor of prognosis as proven by many studies **(7,16-18)**. Other small studies didn’t indicate a significantly worse prognosis of the signet ring subtype **(19,20)**.It was also observed that lymph node involvement is an important prognostic predictor of gastric cancer, as patients with lymph node positive disease were associated with a shorter median OS and PFS compared to those with lymph node negative disease which matches with the results of previous studies **(21)**

Regarding the location of the tumor, the lower third of the stomach was the most commonly affected site in our study representing 43.9% of the included patients who had the antrum and pylorus affected by the tumor. Our results regarding the site are similar to many previous studies **(22,23)**. This could be explained by the prevalence of H.pylori infection and other precancerous lesions which induce gastric mucosal inflammation eventually leading to atrophy, and these atrophic mucosal changes progress from the antrum upwards to the body of the stomach along the lesser curvature, this could explain the higher incidence of Gastro-esophageal cancer in the lower portions of the stomach**(24,25)**.

In this study, the majority of the patients (59.6%) presented with advanced disease (T3 and T4 according to TNM staging). There was a statistically significant difference in the OS between the different disease stages as advanced disease stages were associated with shorter OS with p values = 0.013.This is because this disease becomes symptomatic in advanced stages, moreover, there are no mass screening programs in Egypt for Gastric cancer as it is expensive, and these programs are recommended only in regions with a high incidence as East Asia**(26)**

In our study, 56.2% of the included patients presented with metastasis, where the most common site affected is the peritoneum followed by the liver and this could be correlated with the presence of signet ring appearance in 57.3% of the cohort as the rates of peritoneal dissemination in advanced patients with signet ring cell subtype is higher than those with no signet ring appearance, and this is matched with previous studies with similar results **(27,28)**.

In our cohort of patients, Subtotal gastrectomy with D1 lymphadenectomy was the commonest procedure done, where all patients underwent open surgery (not laparoscopic) and R0 (negative margins) could be achieved in all patients, surgical resection had a great impact on the OS where there was a statistically significant difference in OS between those who underwent surgical resection and those who didn’t, with median OS 17.4 months vs 8.4 months respectively. On the other hand, D2 lymph node dissection was less widely used, it was performed in 7 patients only and this correlates with the results of previous studies reported that D2 dissection was accompanied by higher rates of mortality and morbidity, and it is a difficult procedure that should be performed by experienced surgeons at highly equipped centers **(29)**. Moreover, according to a highly cited Dutch trial (DGCT) there was no difference in the 5 years survival between the two groups (D1 vs D2)**(30)**.

In our study, neoadjuvant chemotherapy was used in 20 patients, and it was proven to have a significant impact on overall survival, where patients who received neoadjuvant chemotherapy showed significantly longer OS with p values=0.0009 and a median OS of 16.5 months versus 9.8 months for those who didn’t receive neoadjuvant therapy. This matches with the data extracted from previous studies which confirmed the impact of perioperative chemotherapy in improving PFS and OS **(31,32)**.

Moreover, chemotherapy was prescribed on a palliative basis in the metastatic setting for 49 patients (55.1%) and fluoropyrimidine-based protocols were the commonest. FOLFOX was the most frequently used protocol as first line, as it was tolerable by most of the patients, while only 3 patients received single agent chemotherapy due to poor performance status. Anthracycline-based chemotherapy was used at first in the adjuvant setting for 20% of the patients then shifted to the fluoropyrimidine-based regimens as they are less toxic to the patients with fewer side effects. After progression on the first line chemotherapy which was used in the metastatic setting, eighteen patients received 2nd line chemotherapy, where Carboplatin/Paclitaxel was the most commonly used regimen which was an effective regimen with acceptable toxicity and this matches with data from numerous studies that showed the efficacy of this regimen in the metastatic setting**(33,34)**.In this study, the patients who responded favorably after receiving the first line chemotherapy had a prolonged OS compared to patients who progressed on the first line and the survival benefit was significant with a p-value of 0.032.The patients who progressed on the first-line chemotherapy had shorter PFS as well and it was statistically significant with a p-value of 0.012.Finally, we found that the median OS was10.7 months and regarding the PFS the median survival was 24.5 months in our series of cases

**Conclusion and recommendations:**

Surgical resection, use of neoadjuvant chemotherapy and poor histo-pathologic features correlate with the treatment outcomes in gastric cancers treated at our institution. Early and proper treatment of precancerous lesions such as H.pylori infection is recommended as it will lead to a decline in the incidence of gastric cancer.

**Author’s contribution**

Conception or design: KM, MR, MN and EH; Acquisition, analysis or interpretation of data: KM, MR, MN and EH; Drafting the manuscript: KM, MN and EH: revising it critically: KM, MR, MN and EH; Final approval of the manuscript version to be published: KM, MN and EH; Agreement to be accountable for all aspects of the work: KM,MR,MN and EH.

**Funding and Approvals:**

This study was self-funded, and investigators didn't receive any funding from external sources during the study conduction, analysis, or publishing. The study subjects were not offered any financial compensation for participation in the study.

**Acknowledgements:**

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The authors declare no conflict of interest.

**Corresponding Author:**

Karim Nabil Mashhour

Kasr Al-Einy School of Medicine, Clinical Oncology Department, Cairo University, Cairo, 11553, Egypt

Fax number: 37606512 - 37490002

E-mail: [karim.mashhour.81@gmail.com](mailto:karim.mashhour.81@gmail.com)

Tel. (+20) 1006086827

**References:**

1. Bray, Freddie, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, and AhmedinJemal. 2018. “Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.” *Wiley Online Library* 68 (6): 394–424. <https://doi.org/10.3322/caac.21492>.
2. Darwish, H, A Sakr, W Bassam, AGhorab - Arab Journal of Oncology, and undefined 2016. 2016. “10 Years' Experience in the Treatment of Gastric Cancer: A Single Egyptian Cancer Center (NEMROCK).” *Amaac.Org* 9 (3). <https://amaac.org/images/files/PAJO/2016Sep/2016.09.09.03.0202.pdf>.
3. Bae, Jong Myon, and EunHee Kim. 2016. “Epstein-Barr Virus and Gastric Cancer Risk: A Meta-Analysis With Meta-Regression of Case-Control Studies.” *Journal of Preventive Medicine and Public Health = YebangUihakhoe Chi* 49 (2): 97–107. <https://doi.org/10.3961/JPMPH.15.068>.
4. Wroblewski, Lydia E., Richard M. Peek, and Keith T. Wilson. 2010. “Helicobacter Pylori and Gastric Cancer: Factors That Modulate Disease Risk.” *Clinical Microbiology Reviews* 23 (4): 713–39. <https://doi.org/10.1128/CMR.00011-10>.
5. Chen, Yun Chi, Wen Liang Fang, Ruei Fang Wang, Chien An Liu, MuhHwa Yang, Shu Shun Lo, Chew Wen Wu, Anna Fen Yau Li, Yi Ming Shyr, and Kuo Hung Huang. 2016a. “Clinicopathological Variation of Lauren Classification in Gastric Cancer.” *Pathology Oncology Research : POR* 22 (1): 197–202. <https://doi.org/10.1007/S12253-015-9996-6>.
6. Hu, Bing, Nassim el Hajj, Scott Sittler, Nancy Lammert, Robert Barnes, and Aurelia Meloni-Ehrig. 2012. “Gastric Cancer: Classification, Histology and Application of Molecular Pathology.” *Journal of Gastrointestinal Oncology* 3 (3): 251. <https://doi.org/10.3978/J.ISSN.2078-6891.2012.021>.
7. Li, Chen, Sungsoo Kim, Ji Fu Lai, Woo Jin Hyung, Won Hyuk Choi, Seung Ho Choi, and Sung Hoon Noh. 2007a. “Advanced Gastric Carcinoma with Signet Ring Cell Histology.” *Oncology* 72 (1–2): 64–68. https://doi.org/10.1159/000111096. 2007b. “Advanced Gastric Carcinoma with Signet Ring Cell Histology.” *Oncology* 72 (1–2): 64–68. <https://doi.org/10.1159/000111096>
8. Qiu, Miao Zhen, Mu Yan Cai, Dong Sheng Zhang, ZhiQiang Wang, De Shen Wang, Yu Hong Li, and RuiHuaXu. 2013a. “Clinicopathological Characteristics and Prognostic Analysis of Lauren Classification in Gastric Adenocarcinoma in China.” *Journal of Translational Medicine* 11 (1): 1–7. <https://doi.org/10.1186/1479-5876-11-58/TABLES/2>.
9. Siewert, J. R., K. Böttcher, J. D. Roder, R. Busch, P. Hermanek, and H. J. Meyer. 1993. “Prognostic Relevance of Systematic Lymph Node Dissection in Gastric Carcinoma. German Gastric Carcinoma Study Group.” *The British Journal of Surgery* 80 (8): 1015–18. <https://doi.org/10.1002/BJS.1800800829>.
10. Gee, Denise W., and David W. Rattner. 2007. “Management of Gastroesophageal Tumors.” *The Oncologist* 12 (2): 175–85.https://doi.org/10.1634/THEONCOLOGIST.12-2-175.
11. Plukker, J. Th, R. C.J. Verschueren, N. H. Mulder, D. ThSleijfer, and J. Grond. 1991. “Chemotherapy and Surgery for Locally Advanced Cancer of the Cardia and Fundus: Phase II Study with Methotrexate and 5-Fluorouracil.” *The British Journal of Surgery* 78 (8): 955–58. <https://doi.org/10.1002/BJS.1800780820>.
12. Cunningham, David, William H. Allum, Sally P. Stenning, Jeremy N. Thompson, Cornelis J.H. van de Velde, Marianne Nicolson, J. Howard Scarffe, et al. 2006a. “Perioperative Chemotherapy versus Surgery Alone for ResectableGastroesophageal Cancer.” *The New England Journal of Medicine* 355 (1): 11–20. <https://doi.org/10.1056/NEJMOA055531>.
13. Schuhmacher, Christoph, Stephan Gretschel, Florian Lordick, Peter Reichardt, Werner Hohenberger, Claus F. Eisenberger, Cornelie Haag, et al. 2010. “Neoadjuvant Chemotherapy Compared with Surgery Alone for Locally Advanced Cancer of the Stomach and Cardia: European Organisation for Research and Treatment of Cancer Randomized Trial 40954.” *Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology* 28 (35): 5210–18. <https://doi.org/10.1200/JCO.2009.26.6114>
14. Rugge, Massimo, MatteoFassan, David Y Graham, M Rugge, M Fassan, and D Y Graham. 2015. “Epidemiology of Gastric Cancer.” *Springer*, January, 23–34. <https://doi.org/10.1007/978-3-319-15826-6_2>.
15. Arnold, Melina, Jin Young Park, M. Constanza Camargo, NunoLunet, David Forman, and Isabelle Soerjomataram. 2020. “Is Gastric Cancer Becoming a Rare Disease? A Global Assessment of Predicted Incidence Trends to 2035.” *Gut* 69 (5): 823–29. <https://doi.org/10.1136/GUTJNL-2019-320234>.
16. KonKim, and Jae Hyuk Lee. 2004. “Clinicopathological Characteristics of Signet Ring Cell Carcinoma of the Stomach.” *ANZ Journal of Surgery* 74 (12): 1060–64. <https://doi.org/10.1111/J.1445-1433.2004.03268.X>
17. Kim, J. P., S. C. Kim, and H. K. Yang. 1994. “Prognostic Significance of Signet Ring Cell Carcinoma of the Stomach.” *Surgical Oncology* 3 (4): 221–27. <https://doi.org/10.1016/0960-7404(94)90037-X>
18. Cunningham, Steven C, Min P Kim, SommerHammoud, RaqeebHaque, AnirbanMaitra, Elizabeth Montgomery, Richard E Heitmiller, Michael A Choti, Keith D Lillemoe, and John L Cameron. 2005. “Survival after Gastric Adenocarcinoma Resection: Eighteen-Year Experience at a Single Institution.” *Springer* 9 (5): 718–25. <https://doi.org/10.1016/j.gassur.2004.12.002>
19. Kim, Dong Yi, Young Kyu Park, Jae KyoonJoo, SeongYeobRyu, Young Jin Kim, Shin Kon Kim, and Jae Hyuk Lee. 2004. “Clinicopathological Characteristics of Signet Ring Cell Carcinoma of the Stomach.” *ANZ Journal of Surgery* 74 (12): 1060–64. <https://doi.org/10.1111/J.1445-1433.2004.03268.X>
20. Kunisaki, C., H. Shimada, M. Nomura, G. Matsuda, Y. Otsuka, and H. Akiyama. 2004. “Therapeutic Strategy for Signet Ring Cell Carcinoma of the Stomach.” *The British Journal of Surgery* 91 (10): 1319–24. <https://doi.org/10.1002/BJS.4637>.
21. Deng, Jing Yu, and Han Liang. 2014. “Clinical Significance of Lymph Node Metastasis in Gastric Cancer.” *World Journal of Gastroenterology : WJG* 20 (14): 3967. <https://doi.org/10.3748/WJG.V20.I14.3967>.
22. Kang, Dae Hwan, CheolWoong Choi, HyungWook Kim, Su Bum Park, Su Jin Kim, HyeongSeok Nam, and DaeGonRyu. 2017. “Location Characteristics of Early Gastric Cancer Treated with Endoscopic Submucosal Dissection.” *Surgical Endoscopy* 31 (11): 4673–79. <https://doi.org/10.1007/S00464-017-5534-9>.
23. Hahn, KyuYeon, Chan Hyuk Park, Yong Kang Lee, Hyunsoo Chung, Jun Chul Park, Sung Kwan Shin, Yong Chan Lee, et al. 2018. “Comparative Study between Endoscopic Submucosal Dissection and Surgery in Patients with Early Gastric Cancer.” *Surgical Endoscopy* 32 (1): 73–86. <https://doi.org/10.1007/S00464-017-5640-8>.
24. Kimura, K., K. Satoh, K. Ido, Y. Taniguchi, T. Takimoto, and T. Takemoto. 1996. “Gastritis in the Japanese Stomach.” *Scandinavian Journal of Gastroenterology. Supplement* 214 (214): 17–20. <https://doi.org/10.3109/00365529609094509>.Zhang, Tai, Beihua Zhang, WendeTian, Xiangxue Ma, Fengyun Wang, Ping Wang, Yuchen Wei, Lin Liu, and Xudong Tang. 2022. “A Bibliometric Analysis of Atrophic Gastritis From 2011 to 2021.” *Frontiers in Medicine* 9 (February): 843395. <https://doi.org/10.3389/fmed.2022.843395>.
25. Leung, Wai K., Ming shiang Wu, YasuoKakugawa, Jae J. Kim, Khay guan Yeoh, Khean Lee Goh, Kai chun Wu, et al. 2008. “Screening for Gastric Cancer in Asia: Current Evidence and Practice.” *The Lancet. Oncology* 9 (3): 279–87. <https://doi.org/10.1016/S1470-2045(08)70072-X>.
26. Kao, Yi Chu, Wen Liang Fang, Ruei Fang Wang, Anna Fen Yau Li, MuhHwa Yang, Chew Wun Wu, Yi Ming Shyr, and Kuo Hung Huang. 2019. “Clinicopathological Differences in Signet Ring Cell Adenocarcinoma between Early and Advanced Gastric Cancer.” *Gastric Cancer* 22 (2): 255–63. <https://doi.org/10.1007/S10120-018-0860-8/TABLES/4>.
27. Li, Y., X. W. Xue, Y. F. Luo, H. W. Wu, J. Chen, and W. X. Zhou. 2018. “[Clinicopathologic Features of Gastric Adenocarcinoma Based on the Revised Lauren’s Classification].” *Zhonghua Bing Li XueZaZhi = Chinese Journal of Pathology* 47 (7): 486–91. <https://doi.org/10.3760/CMA.J.ISSN.0529-5807.2018.07.002>.
28. Yu, W., G. S. Choi, and H. Y. Chung. 2006. “Randomized Clinical Trial of Splenectomy versus Splenic Preservation in Patients with Proximal Gastric Cancer.” *British Journal of Surgery* 93 (5): 559–63. <https://doi.org/10.1002/BJS.5353>.
29. Hartgritik, H. H., C. J.H. van de Velde, H. Putter, J. J. Bonenkamp, E. Klein Kranenbarg, I. Songun, K. Welvaart, et al. 2004. “Extended Lymph Node Dissection for Gastric Cancer: Who May Benefit? Final Results of the Randomized Dutch Gastric Cancer Group Trial.” *Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology* 22 (11): 2069–77. <https://doi.org/10.1200/JCO.2004.08.026>.
30. Cunningham, David, William H. Allum, Sally P. Stenning, Jeremy N. Thompson, Cornelis J.H. van de Velde, Marianne Nicolson, J. Howard Scarffe, et al. 2006a. “Perioperative Chemotherapy versus Surgery Alone for ResectableGastroesophageal Cancer.” *The New England Journal of Medicine* 355 (1): 11–20. <https://doi.org/10.1056/NEJMOA055531.2006b>
31. Ychou, Marc, ValérieBoige, Jean-Pierre Pignon, Thierry Conroy, Olivier Bouché, Gilles Lebreton, Muriel Ducourtieux, et al. 2011. “Perioperative Chemotherapy Compared with Surgery Alone for ResectableGastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial.” *Cinj.Org* 29: 1715–21. <https://doi.org/10.1200/JCO.2010.33.0597>.
32. Smith, David C., Christopher H. Chay, Rodney L. Dunn, Jude Fardig, Peg Esper, Karin Olson, and Kenneth J. Pienta. 2003. “Phase II Trial of Paclitaxel, Estramustine, Etoposide, and Carboplatin in the Treatment of Patients with Hormone-Refractory Prostate Carcinoma.” *Cancer* 98 (2): 269–76. <https://doi.org/10.1002/cncr.11494>.
33. Prithviraj, G. K., K. Baksh, W. Fulp, K. Meredith, S. Hoffe, R. Shridhar, and K. Almhanna. 2015. “Carboplatin and Paclitaxel as First-Line Treatment of Unresectable or Metastatic Esophageal or Gastric Cancer.” *Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus* 28 (8): 782–87. <https://doi.org/10.1111/DOTE.12279>.

12/22/2022